Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.

Human pathology - 1 Nov 2023

D'Angelo Emanuela, Espinosa Iñigo, Felicioni Lara, Buttitta Fiamma, Prat Jaime

Abstract excerpt

Thirteen years ago, we pointed out that ovarian transitional cell carcinomas (TCCs) and conventional high-grade serous carcinomas (HGSCs) had similar genetic alterations and clinical behavior. Consequently, ovarian TCC is now classified as a morphologic variant of HGSC. Defective homologous recombination, resulting from genetic or epigenetic inactivation of DNA damage repair genes, such as BRCA1/2, occurs in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein
Share to Carcinoma, Endometrioid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ovarian Epithelial

Share to Cystadenocarcinoma, Serous

Share to Homologous Recombination

Share to Ovarian Neoplasms

Share to Peritoneal Neoplasms

Source

Identifiers

PMID: 37673346
DOI: 10.1016/j.humpath.2023.08.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ovarian high-grade serous carcinoma with transitional-like (SET) morphology: a homologous recombination-deficient tumor.PMID 37673346Read ↗

Homologous recombination deficiency in high-grade serous ovarian carcinoma: clinical pathological characteristics, impact of neoadjuvant chemotherapy, and prognostic implications.Semantic proximity Read ↗

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis groupSemantic proximity Read ↗

Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the MoonSemantic proximity Read ↗

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas.Semantic proximity Read ↗

Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma?: Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study.Semantic proximity Read ↗

Concurrent RB1 loss and<i>BRCA</i>-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinomaSemantic proximity Read ↗

Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinomaSemantic proximity Read ↗

RB1 expression and HR proficiency define a poor-outcome molecular subtype of high grade serous ovarian carcinomaSemantic proximity Read ↗

Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.Semantic proximity Read ↗

The genesis and evolution of high-grade serous ovarian cancer.Semantic proximity Read ↗

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitorsSemantic proximity Read ↗

Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.